All In Biotech

Drug Trial Radar · NCT00846365

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Mar 13, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,085 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,085

Actual

Start

Mar 2009

Primary completion

Jun 2010

Study completion Jun 2010

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Feb 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.

Conditions

  • Essential Hypertension

Interventions

  • Azilsartan medoxomil and chlorthalidoneDrug

    Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.

  • Azilsartan medoxomil and chlorthalidoneDrug

    Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.

  • Olmesartan medoxomil-hydrochlorothiazideDrug

    Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.Time frame: Baseline and Week 8.

Locations

80 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Haleyville, Alabama

  • Site not named

    Hueytown, Alabama

  • Site not named

    Jasper, Alabama

  • Site not named

    Tallassee, Alabama

  • Site not named

    Green Valley, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Long Beach, California

  • Site not named

    National City, California

  • Site not named

    Roseville, California

  • Site not named

    San Francisco, California

  • Site not named

    San Jose, California

  • Site not named

    Newark, Delaware

  • Site not named

    Clearwater, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jupiter, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Plant City, Florida

  • Site not named

    Tallahassee, Florida

  • Site not named

    Arlington Heights, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Gurnee, Illinois

  • Site not named

    Avon, Indiana

  • Site not named

    Wichita, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Auburn, Maine

  • Site not named

    Baltimore, Maryland

  • Site not named

    Brockton, Massachusetts

  • Site not named

    Haverhill, Massachusetts

  • Site not named

    North Dartmouth, Massachusetts

  • Site not named

    Bingham Farms, Michigan

  • Site not named

    Stevensville, Michigan

  • Site not named

    Olive Branch, Mississippi

  • Site not named

    Kansas City, Missouri

  • Site not named

    New York, New York

  • Site not named

    Burlington, North Carolina

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Hickory, North Carolina

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.